Waypoint Wealth Partners Inc. Purchases Shares of 1,983 Abbott Laboratories $ABT

Key Points

• Waypoint Wealth Partners Inc. has acquired 1,983 shares of Abbott Laboratories, valued at approximately $270,000, marking a new investment position in the healthcare company.
• Abbott Laboratories reported earnings of **$1.26 per share** for the last quarter, *matching expectations*, with total revenue of **$11.14 billion**, exceeding analysts' predictions.
• Institutional investors hold **75.18%** of Abbott Laboratories, with several increasing their stakes, indicating strong confidence in the company’s future performance.

Waypoint Wealth Partners Inc. purchased a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,983 shares of the healthcare product maker's stock, valued at approximately $270,000.

Several other institutional investors have also recently made changes to their positions in the stock. NorthCrest Asset Manangement LLC raised its stake in shares of Abbott Laboratories by 7.7% in the second quarter. NorthCrest Asset Manangement LLC now owns 67,561 shares of the healthcare product maker's stock worth $9,083,000 after buying an additional 4,809 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Abbott Laboratories by 24.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 1,338,060 shares of the healthcare product maker's stock valued at $179,889,000 after buying an additional 263,216 shares in the last quarter. Strathmore Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $511,000. Atticus Wealth Management LLC lifted its stake in shares of Abbott Laboratories by 32.4% in the 2nd quarter. Atticus Wealth Management LLC now owns 3,511 shares of the healthcare product maker's stock valued at $478,000 after purchasing an additional 860 shares during the last quarter. Finally, Bath Savings Trust Co lifted its stake in shares of Abbott Laboratories by 1.3% during the 2nd quarter. Bath Savings Trust Co now owns 168,871 shares of the healthcare product maker's stock worth $22,968,000 after acquiring an additional 2,127 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company's stock.

Abbott Laboratories Trading Up 1.2%

Shares of ABT traded up $1.65 during midday trading on Friday, hitting $136.22. 11,531,874 shares of the stock were exchanged, compared to its average volume of 4,828,819. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The stock has a fifty day simple moving average of $130.47 and a 200 day simple moving average of $131.19. The firm has a market cap of $237.09 billion, a P/E ratio of 17.07, a P/E/G ratio of 2.55 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company's quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Morgan Stanley boosted their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Evercore ISI boosted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. BTIG Research reduced their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Finally, Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.22.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.